How big is the neoantigen vaccine market?

Q: How big is the neoantigen vaccine market?

Market Analysis and Insights Global Neoantigen Vaccine MarketThe global Neoantigen Vaccine market size is projected to reach US million by 2028 from US million in 2021 at a CAGR of during 20222028.Fully considering the economic change by this health crisis Personalized Vaccine accounting for of the Neoantigen Vaccine global market in 2021 is projected to value US million by 2028 growing at a revised CAGR in the postCOVID19 period.

BUY CHAPTERS

Global Neoantigen Vaccine Market Insights, Forecast to 2028

Code: QYRE-Auto-21O10242

Report

March 2022

Pages:127

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Neoantigen Vaccine Market

The global Neoantigen Vaccine market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

Fully considering the economic change by this health crisis, Personalized Vaccine accounting for % of the Neoantigen Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Lung Cancer segment is altered to an % CAGR throughout this forecast period.

China Neoantigen Vaccine market size is valued at US$ million in 2021, while the North America and Europe Neoantigen Vaccine are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Neoantigen Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neoantigen Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neoantigen Vaccine market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neoantigen Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neoantigen Vaccine market.

Neoantigen Vaccine market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neoantigen Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

By Type

Personalized Vaccine
Off-the shelf Vaccine

By Application

Lung Cancer
Melanoma Cancer
Gastrointestinal Cancer
Brain Cancer
Others

By Company

Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom

By Region

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

1 Report Business Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neoantigen Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Personalized Vaccine

1.2.3 Off-the shelf Vaccine

1.3 Market by Application

1.3.1 Global Neoantigen Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Lung Cancer

1.3.3 Melanoma Cancer

1.3.4 Gastrointestinal Cancer

1.3.5 Brain Cancer

1.3.6 Others

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Neoantigen Vaccine Market Perspective (2017-2028)

2.2 Neoantigen Vaccine Growth Trends by Region

2.2.1 Neoantigen Vaccine Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Neoantigen Vaccine Historic Market Size by Region (2017-2022)

2.2.3 Neoantigen Vaccine Forecasted Market Size by Region (2023-2028)

2.3 Neoantigen Vaccine Market Dynamics

2.3.1 Neoantigen Vaccine Industry Trends

2.3.2 Neoantigen Vaccine Market Drivers

2.3.3 Neoantigen Vaccine Market Challenges

2.3.4 Neoantigen Vaccine Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neoantigen Vaccine Players by Revenue

3.1.1 Global Top Neoantigen Vaccine Players by Revenue (2017-2022)

3.1.2 Global Neoantigen Vaccine Revenue Market Share by Players (2017-2022)

3.2 Global Neoantigen Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Neoantigen Vaccine Revenue

3.4 Global Neoantigen Vaccine Market Concentration Ratio

3.4.1 Global Neoantigen Vaccine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Vaccine Revenue in 2021

3.5 Neoantigen Vaccine Key Players Head office and Area Served

3.6 Key Players Neoantigen Vaccine Product Solution and Service

3.7 Date of Enter into Neoantigen Vaccine Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Neoantigen Vaccine Breakdown Data by Type

4.1 Global Neoantigen Vaccine Historic Market Size by Type (2017-2022)

4.2 Global Neoantigen Vaccine Forecasted Market Size by Type (2023-2028)

5 Neoantigen Vaccine Breakdown Data by Application

5.1 Global Neoantigen Vaccine Historic Market Size by Application (2017-2022)

5.2 Global Neoantigen Vaccine Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Neoantigen Vaccine Market Size (2017-2028)

6.2 North America Neoantigen Vaccine Market Size by Type

6.2.1 North America Neoantigen Vaccine Market Size by Type (2017-2022)

6.2.2 North America Neoantigen Vaccine Market Size by Type (2023-2028)

6.2.3 North America Neoantigen Vaccine Market Share by Type (2017-2028)

6.3 North America Neoantigen Vaccine Market Size by Application

6.3.1 North America Neoantigen Vaccine Market Size by Application (2017-2022)

6.3.2 North America Neoantigen Vaccine Market Size by Application (2023-2028)

6.3.3 North America Neoantigen Vaccine Market Share by Application (2017-2028)

6.4 North America Neoantigen Vaccine Market Size by Country

6.4.1 North America Neoantigen Vaccine Market Size by Country (2017-2022)

6.4.2 North America Neoantigen Vaccine Market Size by Country (2023-2028)

6.4.3 United States

6.4.4 Canada

7 Europe

7.1 Europe Neoantigen Vaccine Market Size (2017-2028)

7.2 Europe Neoantigen Vaccine Market Size by Type

7.2.1 Europe Neoantigen Vaccine Market Size by Type (2017-2022)

7.2.2 Europe Neoantigen Vaccine Market Size by Type (2023-2028)

7.2.3 Europe Neoantigen Vaccine Market Share by Type (2017-2028)

7.3 Europe Neoantigen Vaccine Market Size by Application

7.3.1 Europe Neoantigen Vaccine Market Size by Application (2017-2022)

7.3.2 Europe Neoantigen Vaccine Market Size by Application (2023-2028)

7.3.3 Europe Neoantigen Vaccine Market Share by Application (2017-2028)

7.4 Europe Neoantigen Vaccine Market Size by Country

7.4.1 Europe Neoantigen Vaccine Market Size by Country (2017-2022)

7.4.2 Europe Neoantigen Vaccine Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neoantigen Vaccine Market Size (2017-2028)

8.2 Asia-Pacific Neoantigen Vaccine Market Size by Type

8.2.1 Asia-Pacific Neoantigen Vaccine Market Size by Type (2017-2022)

8.2.2 Asia-Pacific Neoantigen Vaccine Market Size by Type (2023-2028)

8.2.3 Asia-Pacific Neoantigen Vaccine Market Share by Type (2017-2028)

8.3 Asia-Pacific Neoantigen Vaccine Market Size by Application

8.3.1 Asia-Pacific Neoantigen Vaccine Market Size by Application (2017-2022)

8.3.2 Asia-Pacific Neoantigen Vaccine Market Size by Application (2023-2028)

8.3.3 Asia-Pacific Neoantigen Vaccine Market Share by Application (2017-2028)

8.4 Asia-Pacific Neoantigen Vaccine Market Size by Region

8.4.1 Asia-Pacific Neoantigen Vaccine Market Size by Region (2017-2022)

8.4.2 Asia-Pacific Neoantigen Vaccine Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9 Latin America

9.1 Latin America Neoantigen Vaccine Market Size (2017-2028)

9.2 Latin America Neoantigen Vaccine Market Size by Type

9.2.1 Latin America Neoantigen Vaccine Market Size by Type (2017-2022)

9.2.2 Latin America Neoantigen Vaccine Market Size by Type (2023-2028)

9.2.3 Latin America Neoantigen Vaccine Market Share by Type (2017-2028)

9.3 Latin America Neoantigen Vaccine Market Size by Application

9.3.1 Latin America Neoantigen Vaccine Market Size by Application (2017-2022)

9.3.2 Latin America Neoantigen Vaccine Market Size by Application (2023-2028)

9.3.3 Latin America Neoantigen Vaccine Market Share by Application (2017-2028)

9.4 Latin America Neoantigen Vaccine Market Size by Country

9.4.1 Latin America Neoantigen Vaccine Market Size by Country (2017-2022)

9.4.2 Latin America Neoantigen Vaccine Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neoantigen Vaccine Market Size (2017-2028)

10.2 Middle East & Africa Neoantigen Vaccine Market Size by Type

10.2.1 Middle East & Africa Neoantigen Vaccine Market Size by Type (2017-2022)

10.2.2 Middle East & Africa Neoantigen Vaccine Market Size by Type (2023-2028)

10.2.3 Middle East & Africa Neoantigen Vaccine Market Share by Type (2017-2028)

10.3 Middle East & Africa Neoantigen Vaccine Market Size by Application

10.3.1 Middle East & Africa Neoantigen Vaccine Market Size by Application (2017-2022)

10.3.2 Middle East & Africa Neoantigen Vaccine Market Size by Application (2023-2028)

10.3.3 Middle East & Africa Neoantigen Vaccine Market Share by Application (2017-2028)

10.4 Middle East & Africa Neoantigen Vaccine Market Size by Country

10.4.1 Middle East & Africa Neoantigen Vaccine Market Size by Country (2017-2022)

10.4.2 Middle East & Africa Neoantigen Vaccine Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neoantigen Vaccine Introduction

11.1.4 Pfizer Revenue in Neoantigen Vaccine Business (2017-2022)

11.1.5 Pfizer Recent Developments

11.2 Merck & Co Inc

11.2.1 Merck & Co Inc Company Details

11.2.2 Merck & Co Inc Business Overview

11.2.3 Merck & Co Inc Neoantigen Vaccine Introduction

11.2.4 Merck & Co Inc Revenue in Neoantigen Vaccine Business (2017-2022)

11.2.5 Merck & Co Inc Recent Developments

11.3 Eli Lilly and Company

11.3.1 Eli Lilly and Company Company Details

11.3.2 Eli Lilly and Company Business Overview

11.3.3 Eli Lilly and Company Neoantigen Vaccine Introduction

11.3.4 Eli Lilly and Company Revenue in Neoantigen Vaccine Business (2017-2022)

11.3.5 Eli Lilly and Company Recent Developments

11.4 BioNTech

11.4.1 BioNTech Company Details

11.4.2 BioNTech Business Overview

11.4.3 BioNTech Neoantigen Vaccine Introduction

11.4.4 BioNTech Revenue in Neoantigen Vaccine Business (2017-2022)

11.4.5 BioNTech Recent Developments

11.5 Roche Holding AG

11.5.1 Roche Holding AG Company Details

11.5.2 Roche Holding AG Business Overview

11.5.3 Roche Holding AG Neoantigen Vaccine Introduction

11.5.4 Roche Holding AG Revenue in Neoantigen Vaccine Business (2017-2022)

11.5.5 Roche Holding AG Recent Developments

11.6 OSE Immunotherapeutics

11.6.1 OSE Immunotherapeutics Company Details

11.6.2 OSE Immunotherapeutics Business Overview

11.6.3 OSE Immunotherapeutics Neoantigen Vaccine Introduction

11.6.4 OSE Immunotherapeutics Revenue in Neoantigen Vaccine Business (2017-2022)

11.6.5 OSE Immunotherapeutics Recent Developments

11.7 Gritstone Bio

11.7.1 Gritstone Bio Company Details

11.7.2 Gritstone Bio Business Overview

11.7.3 Gritstone Bio Neoantigen Vaccine Introduction

11.7.4 Gritstone Bio Revenue in Neoantigen Vaccine Business (2017-2022)

11.7.5 Gritstone Bio Recent Developments

11.8 Moderna

11.8.1 Moderna Company Details

11.8.2 Moderna Business Overview

11.8.3 Moderna Neoantigen Vaccine Introduction

11.8.4 Moderna Revenue in Neoantigen Vaccine Business (2017-2022)

11.8.5 Moderna Recent Developments

11.9 Avidea Technologies

11.9.1 Avidea Technologies Company Details

11.9.2 Avidea Technologies Business Overview

11.9.3 Avidea Technologies Neoantigen Vaccine Introduction

11.9.4 Avidea Technologies Revenue in Neoantigen Vaccine Business (2017-2022)

11.9.5 Avidea Technologies Recent Developments

11.10 Vaccibody AS

11.10.1 Vaccibody AS Company Details

11.10.2 Vaccibody AS Business Overview

11.10.3 Vaccibody AS Neoantigen Vaccine Introduction

11.10.4 Vaccibody AS Revenue in Neoantigen Vaccine Business (2017-2022)

11.10.5 Vaccibody AS Recent Developments

11.11 Agenus Inc

11.11.1 Agenus Inc Company Details

11.11.2 Agenus Inc Business Overview

11.11.3 Agenus Inc Neoantigen Vaccine Introduction

11.11.4 Agenus Inc Revenue in Neoantigen Vaccine Business (2017-2022)

11.11.5 Agenus Inc Recent Developments

11.12 Novogene

11.12.1 Novogene Company Details

11.12.2 Novogene Business Overview

11.12.3 Novogene Neoantigen Vaccine Introduction

11.12.4 Novogene Revenue in Neoantigen Vaccine Business (2017-2022)

11.12.5 Novogene Recent Developments

11.13 ZIOPHARM Oncology

11.13.1 ZIOPHARM Oncology Company Details

11.13.2 ZIOPHARM Oncology Business Overview

11.13.3 ZIOPHARM Oncology Neoantigen Vaccine Introduction

11.13.4 ZIOPHARM Oncology Revenue in Neoantigen Vaccine Business (2017-2022)

11.13.5 ZIOPHARM Oncology Recent Developments

11.14 ISA Pharmaceuticals

11.14.1 ISA Pharmaceuticals Company Details

11.14.2 ISA Pharmaceuticals Business Overview

11.14.3 ISA Pharmaceuticals Neoantigen Vaccine Introduction

11.14.4 ISA Pharmaceuticals Revenue in Neoantigen Vaccine Business (2017-2022)

11.14.5 ISA Pharmaceuticals Recent Developments

11.15 BrightPath Biotherapeutics

11.15.1 BrightPath Biotherapeutics Company Details

11.15.2 BrightPath Biotherapeutics Business Overview

11.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Introduction

11.15.4 BrightPath Biotherapeutics Revenue in Neoantigen Vaccine Business (2017-2022)

11.15.5 BrightPath Biotherapeutics Recent Developments

11.16 Vaximm AG

11.16.1 Vaximm AG Company Details

11.16.2 Vaximm AG Business Overview

11.16.3 Vaximm AG Neoantigen Vaccine Introduction

11.16.4 Vaximm AG Revenue in Neoantigen Vaccine Business (2017-2022)

11.16.5 Vaximm AG Recent Developments

11.17 Medigene AG

11.17.1 Medigene AG Company Details

11.17.2 Medigene AG Business Overview

11.17.3 Medigene AG Neoantigen Vaccine Introduction

11.17.4 Medigene AG Revenue in Neoantigen Vaccine Business (2017-2022)

11.17.5 Medigene AG Recent Developments

11.18 Genocea Biosciences Inc

11.18.1 Genocea Biosciences Inc Company Details

11.18.2 Genocea Biosciences Inc Business Overview

11.18.3 Genocea Biosciences Inc Neoantigen Vaccine Introduction

11.18.4 Genocea Biosciences Inc Revenue in Neoantigen Vaccine Business (2017-2022)

11.18.5 Genocea Biosciences Inc Recent Developments

11.19 Advaxis

11.19.1 Advaxis Company Details

11.19.2 Advaxis Business Overview

11.19.3 Advaxis Neoantigen Vaccine Introduction

11.19.4 Advaxis Revenue in Neoantigen Vaccine Business (2017-2022)

11.19.5 Advaxis Recent Developments

11.20 Nouscom

11.20.1 Nouscom Company Details

11.20.2 Nouscom Business Overview

11.20.3 Nouscom Neoantigen Vaccine Introduction

11.20.4 Nouscom Revenue in Neoantigen Vaccine Business (2017-2022)

11.20.5 Nouscom Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Neoantigen Vaccine Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

Table 2. Key Players of Personalized Vaccine

Table 3. Key Players of Off-the shelf Vaccine

Table 4. Global Neoantigen Vaccine Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

Table 5. Global Neoantigen Vaccine Market Size by Region (US$ Million): 2017 VS 2021 VS 2028

Table 6. Global Neoantigen Vaccine Market Size by Region (2017-2022) & (US$ Million)

Table 7. Global Neoantigen Vaccine Market Share by Region (2017-2022)

Table 8. Global Neoantigen Vaccine Forecasted Market Size by Region (2023-2028) & (US$ Million)

Table 9. Global Neoantigen Vaccine Market Share by Region (2023-2028)

Table 10. Neoantigen Vaccine Market Trends

Table 11. Neoantigen Vaccine Market Drivers

Table 12. Neoantigen Vaccine Market Challenges

Table 13. Neoantigen Vaccine Market Restraints

Table 14. Global Neoantigen Vaccine Revenue by Players (2017-2022) & (US$ Million)

Table 15. Global Neoantigen Vaccine Revenue Share by Players (2017-2022)

Table 16. Global Top Neoantigen Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Vaccine as of 2021)

Table 17. Ranking of Global Top Neoantigen Vaccine Companies by Revenue (US$ Million) in 2021

Table 18. Global 5 Largest Players Market Share by Neoantigen Vaccine Revenue (CR5 and HHI) & (2017-2022)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Neoantigen Vaccine Product Solution and Service

Table 21. Date of Enter into Neoantigen Vaccine Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Neoantigen Vaccine Market Size by Type (2017-2022) & (US$ Million)

Table 24. Global Neoantigen Vaccine Revenue Market Share by Type (2017-2022)

Table 25. Global Neoantigen Vaccine Forecasted Market Size by Type (2023-2028) & (US$ Million)

Table 26. Global Neoantigen Vaccine Revenue Market Share by Type (2023-2028)

Table 27. Global Neoantigen Vaccine Market Size by Application (2017-2022) & (US$ Million)

Table 28. Global Neoantigen Vaccine Revenue Share by Application (2017-2022)

Table 29. Global Neoantigen Vaccine Forecasted Market Size by Application (2023-2028) & (US$ Million)

Table 30. Global Neoantigen Vaccine Revenue Share by Application (2023-2028)

Table 31. North America Neoantigen Vaccine Market Size by Type (2017-2022) & (US$ Million)

Table 32. North America Neoantigen Vaccine Market Size by Type (2023-2028) & (US$ Million)

Table 33. North America Neoantigen Vaccine Market Size by Application (2017-2022) & (US$ Million)

Table 34. North America Neoantigen Vaccine Market Size by Application (2023-2028) & (US$ Million)

Table 35. North America Neoantigen Vaccine Market Size by Country (2017-2022) & (US$ Million)

Table 36. North America Neoantigen Vaccine Market Size by Country (2023-2028) & (US$ Million)

Table 37. Europe Neoantigen Vaccine Market Size by Type (2017-2022) & (US$ Million)

Table 38. Europe Neoantigen Vaccine Market Size by Type (2023-2028) & (US$ Million)

Table 39. Europe Neoantigen Vaccine Market Size by Application (2017-2022) & (US$ Million)

Table 40. Europe Neoantigen Vaccine Market Size by Application (2023-2028) & (US$ Million)

Table 41. Europe Neoantigen Vaccine Market Size by Country (2017-2022) & (US$ Million)

Table 42. Europe Neoantigen Vaccine Market Size by Country (2023-2028) & (US$ Million)

Table 43. Asia Pacific Neoantigen Vaccine Market Size by Type (2017-2022) & (US$ Million)

Table 44. Asia Pacific Neoantigen Vaccine Market Size by Type (2023-2028) & (US$ Million)

Table 45. Asia Pacific Neoantigen Vaccine Market Size by Application (2017-2022) & (US$ Million)

Table 46. Asia Pacific Neoantigen Vaccine Market Size by Application (2023-2028) & (US$ Million)

Table 47. Asia Pacific Neoantigen Vaccine Market Size by Region (2017-2022) & (US$ Million)

Table 48. Asia Pacific Neoantigen Vaccine Market Size by Region (2023-2028) & (US$ Million)

Table 49. Latin America Neoantigen Vaccine Market Size by Type (2017-2022) & (US$ Million)

Table 50. Latin America Neoantigen Vaccine Market Size by Type (2023-2028) & (US$ Million)

Table 51. Latin America Neoantigen Vaccine Market Size by Application (2017-2022) & (US$ Million)

Table 52. Latin America Neoantigen Vaccine Market Size by Application (2023-2028) & (US$ Million)

Table 53. Latin America Neoantigen Vaccine Market Size by Country (2017-2022) & (US$ Million)

Table 54. Latin America Neoantigen Vaccine Market Size by Country (2023-2028) & (US$ Million)

Table 55. Middle East and Africa Neoantigen Vaccine Market Size by Type (2017-2022) & (US$ Million)

Table 56. Middle East and Africa Neoantigen Vaccine Market Size by Type (2023-2028) & (US$ Million)

Table 57. Middle East and Africa Neoantigen Vaccine Market Size by Application (2017-2022) & (US$ Million)

Table 58. Middle East and Africa Neoantigen Vaccine Market Size by Application (2023-2028) & (US$ Million)

Table 59. Middle East and Africa Neoantigen Vaccine Market Size by Country (2017-2022) & (US$ Million)

Table 60. Middle East and Africa Neoantigen Vaccine Market Size by Country (2023-2028) & (US$ Million)

Table 61. Pfizer Company Details

Table 62. Pfizer Business Overview

Table 63. Pfizer Neoantigen Vaccine Product

Table 64. Pfizer Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 65. Pfizer Recent Developments

Table 66. Merck & Co Inc Company Details

Table 67. Merck & Co Inc Business Overview

Table 68. Merck & Co Inc Neoantigen Vaccine Product

Table 69. Merck & Co Inc Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 70. Merck & Co Inc Recent Developments

Table 71. Eli Lilly and Company Company Details

Table 72. Eli Lilly and Company Business Overview

Table 73. Eli Lilly and Company Neoantigen Vaccine Product

Table 74. Eli Lilly and Company Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 75. Eli Lilly and Company Recent Developments

Table 76. BioNTech Company Details

Table 77. BioNTech Business Overview

Table 78. BioNTech Neoantigen Vaccine Product

Table 79. BioNTech Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 80. BioNTech Recent Developments

Table 81. Roche Holding AG Company Details

Table 82. Roche Holding AG Business Overview

Table 83. Roche Holding AG Neoantigen Vaccine Product

Table 84. Roche Holding AG Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 85. Roche Holding AG Recent Developments

Table 86. OSE Immunotherapeutics Company Details

Table 87. OSE Immunotherapeutics Business Overview

Table 88. OSE Immunotherapeutics Neoantigen Vaccine Product

Table 89. OSE Immunotherapeutics Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 90. OSE Immunotherapeutics Recent Developments

Table 91. Gritstone Bio Company Details

Table 92. Gritstone Bio Business Overview

Table 93. Gritstone Bio Neoantigen Vaccine Product

Table 94. Gritstone Bio Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 95. Gritstone Bio Recent Developments

Table 96. Moderna Company Details

Table 97. Moderna Business Overview

Table 98. Moderna Neoantigen Vaccine Product

Table 99. Moderna Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 100. Moderna Recent Developments

Table 101. Avidea Technologies Company Details

Table 102. Avidea Technologies Business Overview

Table 103. Avidea Technologies Neoantigen Vaccine Product

Table 104. Avidea Technologies Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 105. Avidea Technologies Recent Developments

Table 106. Vaccibody AS Company Details

Table 107. Vaccibody AS Business Overview

Table 108. Vaccibody AS Neoantigen Vaccine Product

Table 109. Vaccibody AS Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 110. Vaccibody AS Recent Developments

Table 111. Agenus Inc Company Details

Table 112. Agenus Inc Business Overview

Table 113. Agenus Inc Neoantigen Vaccine Product

Table 114. Agenus Inc Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 115. Agenus Inc Recent Developments

Table 116. Novogene Company Details

Table 117. Novogene Business Overview

Table 118. Novogene Neoantigen Vaccine Product

Table 119. Novogene Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 120. Novogene Recent Developments

Table 121. ZIOPHARM Oncology Company Details

Table 122. ZIOPHARM Oncology Business Overview

Table 123. ZIOPHARM Oncology Neoantigen Vaccine Product

Table 124. ZIOPHARM Oncology Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 125. ZIOPHARM Oncology Recent Developments

Table 126. ISA Pharmaceuticals Company Details

Table 127. ISA Pharmaceuticals Business Overview

Table 128. ISA Pharmaceuticals Neoantigen Vaccine Product

Table 129. ISA Pharmaceuticals Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 130. ISA Pharmaceuticals Recent Developments

Table 131. BrightPath Biotherapeutics Company Details

Table 132. BrightPath Biotherapeutics Business Overview

Table 133. BrightPath Biotherapeutics Neoantigen Vaccine Product

Table 134. BrightPath Biotherapeutics Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 135. BrightPath Biotherapeutics Recent Developments

Table 136. Vaximm AG Company Details

Table 137. Vaximm AG Business Overview

Table 138. Vaximm AG Neoantigen Vaccine Product

Table 139. Vaximm AG Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 140. Vaximm AG Recent Developments

Table 141. Medigene AG Company Details

Table 142. Medigene AG Business Overview

Table 143. Medigene AG Neoantigen Vaccine Product

Table 144. Medigene AG Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 145. Medigene AG Recent Developments

Table 146. Genocea Biosciences Inc Company Details

Table 147. Genocea Biosciences Inc Business Overview

Table 148. Genocea Biosciences Inc Neoantigen Vaccine Product

Table 149. Genocea Biosciences Inc Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 150. Genocea Biosciences Inc Recent Developments

Table 151. Advaxis Company Details

Table 152. Advaxis Business Overview

Table 153. Advaxis Neoantigen Vaccine Product

Table 154. Advaxis Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 155. Advaxis Recent Developments

Table 156. Nouscom Company Details

Table 157. Nouscom Business Overview

Table 158. Nouscom Neoantigen Vaccine Product

Table 159. Nouscom Revenue in Neoantigen Vaccine Business (2017-2022) & (US$ Million)

Table 160. Nouscom Recent Developments

Table 161. Research Programs/Design for This Report

Table 162. Key Data Information from Secondary Sources

Table 163. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Neoantigen Vaccine Market Share by Type: 2021 VS 2028

Figure 2. Personalized Vaccine Features

Figure 3. Off-the shelf Vaccine Features

Figure 4. Global Neoantigen Vaccine Market Share by Application: 2021 VS 2028

Figure 5. Lung Cancer Case Studies

Figure 6. Melanoma Cancer Case Studies

Figure 7. Gastrointestinal Cancer Case Studies

Figure 8. Brain Cancer Case Studies

Figure 9. Others Case Studies

Figure 10. Neoantigen Vaccine Report Years Considered

Figure 11. Global Neoantigen Vaccine Market Size (US$ Million), Year-over-Year: 2017-2028

Figure 12. Global Neoantigen Vaccine Market Size, (US$ Million), 2017 VS 2021 VS 2028

Figure 13. Global Neoantigen Vaccine Market Share by Region: 2021 VS 2028

Figure 14. Global Neoantigen Vaccine Market Share by Players in 2021

Figure 15. Global Top Neoantigen Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Vaccine as of 2021)

Figure 16. The Top 10 and 5 Players Market Share by Neoantigen Vaccine Revenue in 2021

Figure 17. North America Neoantigen Vaccine Market Size YoY (2017-2028) & (US$ Million)

Figure 18. North America Neoantigen Vaccine Market Size Market Share by Type (2017-2028)

Figure 19. North America Neoantigen Vaccine Market Size Market Share by Application (2017-2028)

Figure 20. North America Neoantigen Vaccine Market Size Share by Country (2017-2028)

Figure 21. United States Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 22. Canada Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 23. Europe Neoantigen Vaccine Market Size YoY (2017-2028) & (US$ Million)

Figure 24. Europe Neoantigen Vaccine Market Size Market Share by Type (2017-2028)

Figure 25. Europe Neoantigen Vaccine Market Size Market Share by Application (2017-2028)

Figure 26. Europe Neoantigen Vaccine Market Size Share by Country (2017-2028)

Figure 27. Germany Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 28. France Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 29. U.K. Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 30. Italy Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 31. Russia Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 32. Nordic Countries Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 33. Asia-Pacific Neoantigen Vaccine Market Size YoY (2017-2028) & (US$ Million)

Figure 34. Asia Pacific Neoantigen Vaccine Market Size Market Share by Type (2017-2028)

Figure 35. Asia Pacific Neoantigen Vaccine Market Size Market Share by Application (2017-2028)

Figure 36. Asia Pacific Neoantigen Vaccine Market Size Share by Region (2017-2028)

Figure 37. China Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 38. Japan Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 39. South Korea Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 40. Southeast Asia Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 41. India Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 42. Australia Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

Figure 43. Latin America Neoantigen Vaccine Market Size YoY (2017-2028) & (US$ Million)

Figure 44. Latin America Neoantigen Vaccine Market Size Market Share by Type (2017-2028)

Figure 45. Latin America Neoantigen Vaccine Market Size Market Share by Application (2017-2028)

Figure 46. Latin America Neoantigen Vaccine Market Size Share by Country (2017-2028)

Figure 47. Mexico Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 48. Brazil Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 49. Middle East & Africa Neoantigen Vaccine Market Size YoY (2017-2028) & (US$ Million)

Figure 50. Middle East and Africa Neoantigen Vaccine Market Size Market Share by Type (2017-2028)

Figure 51. Middle East and Africa Neoantigen Vaccine Market Size Market Share by Application (2017-2028)

Figure 52. Middle East and Africa Neoantigen Vaccine Market Size Share by Country (2017-2028)

Figure 53. Turkey Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 54. Saudi Arabia Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 55. UAE Neoantigen Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 56. Pfizer Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 57. Merck & Co Inc Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 58. Eli Lilly and Company Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 59. BioNTech Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 60. Roche Holding AG Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 61. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 62. Gritstone Bio Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 63. Moderna Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 64. Avidea Technologies Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 65. Vaccibody AS Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 66. Agenus Inc Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 67. Novogene Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 68. ZIOPHARM Oncology Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 69. ISA Pharmaceuticals Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 70. BrightPath Biotherapeutics Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 71. Vaximm AG Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 72. Medigene AG Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 73. Genocea Biosciences Inc Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 74. Advaxis Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 75. Nouscom Revenue Growth Rate in Neoantigen Vaccine Business (2017-2022)

Figure 76. Bottom-up and Top-down Approaches for This Report

Figure 77. Data Triangulation

Figure 78. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Global Neoantigen Vaccine Market Insights, Forecast to 2028

Published Date: March 2022

Report Code: QYRE-Auto-21O10242

Global Neoantigen Vaccine Market Insights, Forecast to 2028

FEATURED COMPANIES

Neoantigen Vaccine Market

By Type

By Application

By Company

By Region

FEATURED COMPANIES

RELATED REPORTS

$5800

Enterprise User

$5800

Enterprise User

$8000

Enterprise User

$8000

Enterprise User